I
n the times of Aulus Cornelius Celsus (De Medicina, circa AD 25), inflammation had straightforward associations with trauma and infection. Twenty centuries later it is not anymore a feature of hurt legionnaires or gladiators, and diagnosis is made by C-reactive protein (CRP) and other biomarkers, not by pain, swelling, or redness.
Local microbial or sterile reactions are still common after physical injuries related to sports, traffic accidents, or military conflicts; however, the highly prevalent modality nowadays is systemic microinflammation, which is essentially asymptomatic. As current life expectancy by far exceeds the estimated 25 years during the Roman Empire, multiple overlapping associations with inflammation are unveiled in older populations with large degenerative burdens, however, disease-free or at least symptomless. Obesity, tobacco addiction, diabetes, occult microbial conditions (orodental troubles, Helicobacter pylori infection), respiratory conditions, atherosclerosis, and old age itself are just a few examples, so that establishing single links becomes a colossal challenge.
In the present issue, Asferg et al. endeavored to examine inflammatory indices in hypertension by using data from the Copenhagen City Heart Study. 1 Analysis failed to demonstrate any negative consequences for inflammation on blood pressure. In other words, obese individuals with exacerbated acute-phase response exhibited no more risk than trouble-free controls. The authors anticipate that other mechanisms, not elevated CRP and fibrinogen, mediate the impact of obesity on hypertension.
Multiple statistical models were designed and the protocol represents a serious contribution. Nevertheless, a few points deserve further scrutiny. The lack of correlation of CRP but not obesity with hypertension is surprising, as CRP closely follows increased body weight, and especially enlarged waist circumference. In a Japanese population undergoing secondary prevention of cardiovascular disease, it was recently reaffirmed on the basis of logistic regression that CRP maintained linear relationship with visceral obesity, as well as with several other components of the metabolic syndrome. 2 The discussion would become simpler should a mechanistic connection be established between CRP and hypertension.
Direct involvement is not obligatory for a molecular signal but it does seem to exist in atherosclerosis, as CRP has been identified in plaques, as well as in monocytes and tissue macrophages, which are present in the necrotic core of lesions prone to plaque rupture. 3 Arterial stiffness and endothelial dysfunction might be speculated as the equivalent correlates of inflammation and CRP in hypertension. In a recent assessment of the Framingham Heart Study, elevated CRP was incriminated for vascular stiffness, along with the renin and plasminogen cascade. 4 Even more intriguing is the experimental transfection of CRP gene into rats resulting in prolonged hypertension, endothelial dysfunction, and increased stiffness. Elevated expression of receptors for angiotensin type 1, ET-1, and endothelin type A was demonstrated, along with diminished expression of angiotensin type 2 receptor. The phenomenon was probably mediated by reduced NO production. 5 Circumstantial as well as causal evidence highlighting a role for inflammation in hypertension, in parallel with the negative results skillfully provided by Asferg et al., need to be further elaborated. Targeted clinical studies should either advance or refute the concept of pathophysiological impact of subclinical inflammation, perhaps mediated by CRP itself. This topic is current and should not be laid to rest for another 2000 years.
